OCUL Latest Press Releases

-- October 29, 2026 --

Ocular Therapeutix to Participate in November Investor and Scientific Conferences Globe Newswire 7:00 AM

-- October 9, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- October 1, 2026 --

Ocular Therapeutix to Participate in October Scientific and Investor Conferences Globe Newswire 7:00 AM

-- September 18, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- September 15, 2026 --

Ocular Therapeutix Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI in Wet AMD Globe Newswire 7:00 AM

-- September 1, 2026 --

Ocular Therapeutix to Participate in September and October Investor and Scientific Conferences Globe Newswire 7:00 AM

-- August 7, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 3, 2026 --

Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights Globe Newswire 7:00 AM

-- July 9, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 1, 2026 --

Ocular Therapeutix to Participate in July Scientific and Investor Conferences Globe Newswire 7:00 AM

-- June 22, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 17, 2026 --

Ocular Therapeutix Investor Day to Highlight U.S. FDA Alignment on AXPAXLI NDA with Submission Planned for Fourth Quarter 2026 Globe Newswire 8:45 AM

-- June 5, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- June 4, 2026 --

Ocular Therapeutix to Participate in Clinical Trials at the Summit 2026 Globe Newswire 7:00 AM

-- June 2, 2026 --

Ocular Therapeutix to Host Investor Day on June 17, 2026 Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes